Chromium Picolinate for PCOS: Every Trial Dose, Side by Side

How Much Chromium Picolinate Did PCOS Trials Actually Use?

Five placebo- or comparator-controlled trials tested chromium picolinate in PCOS at doses from 200 to 1,000 mcg a day, for anywhere from a few weeks to six months, and the doses do not cluster around one number the way a “standard dose” would suggest. The two trials with the clearest positive results — one in adolescents, one in adults — both happened to use the same 1,000 mcg dose held for six months; the oldest and lowest-dose trial, at 200 mcg with an unstated duration, found a narrower effect.

The Lydic trial is worth reading differently from the other four: it had no placebo arm and measured five people with a gold-standard insulin clamp rather than tracking a group over months, so its 38% figure describes a short-term physiological signal, not a treatment outcome comparable to the other rows.

You may see PCOS written as polyendocrine metabolic ovarian syndrome (PMOS), after a 2026 global consensus of more than 50 organisations renamed it. Nothing about the trial evidence below changed with the name — this article uses PCOS because that is still what most readers search.

Is Chromium Picolinate the Same as Chromium Chloride or GTF Chromium?

No — every trial in the table above used chromium picolinate specifically, and the three forms sold as “chromium” supplements are not interchangeable. Chromium picolinate is chromium bound to picolinic acid, and elemental chromium makes up about 12.4% of its weight; chromium chloride is an inorganic salt; “GTF chromium” is a marketing name for chromium-rich brewer’s yeast, tied to a 1950s–70s theory of a natural “glucose tolerance factor” whose exact structure was never pinned down.

Absorption and elemental-chromium figures above come from the NIH Office of Dietary Supplements chromium fact sheet. If a bottle lists “chromium picolinate 1,000 mcg,” check whether that is the whole-compound weight or the elemental chromium weight the Supplement Facts panel is required to state — the two numbers are not the same, and the trial doses in Table 1 are elemental chromium.

Does Chromium Picolinate Actually Improve Insulin Resistance in PCOS?

A 2025 meta-analysis pooling 10 randomised trials and 683 women with PCOS found chromium supplementation significantly lowered fasting insulin, triglycerides, and total cholesterol, and raised the Quantitative Insulin Sensitivity Check Index and ovulation incidence — and reported chromium picolinate at 200 mcg performed comparably to metformin on fasting glucose, fasting insulin, and pregnancy rate, with fewer side effects. A 2018 systematic review of six of the same general trials reached a more skeptical verdict: limited and inconsistent effects on weight, glucose, lipids, and hormones, concluding more study was needed before recommending it. Both are reading the same small, dose-scattered literature; the difference is which effects each one weighted, not new data one had and the other didn’t.

One of the most-cited chromium-only PCOS trials — a 2015 Iranian randomised trial — was flagged by its journal, Annals of Nutrition & Metabolism, with a formal expression of concern. This page does not cite it and does not rely on its findings; none of the numbers above come from it or from any trial sharing its author group. Where a finding in this space rests on a single research group’s papers, treat it as provisional rather than established until an independent lab reproduces it — several trials above (Lucidi, Lydic, Amooee, Amr, Ashoush) are independent of each other and of that flagged trial.

What Does Chromium Picolinate Do for Ovulation and Periods in PCOS?

Two of five trials found a real cycle effect: Ashoush’s adult trial saw ovulation and regular menstruation roughly double after five months on 1,000 mcg/day, and Amr’s adolescent trial saw the share of participants with oligomenorrhea or amenorrhea fall from 83% to 31% after six months on the same dose. Against that, Amooee’s head-to-head trial found chromium picolinate produced no significant difference in ovulation or pregnancy rate compared with metformin — meaning the cycle-regularity signal above did not translate into a fertility-outcome advantage in the one trial built to measure it. No trial reviewed here used live birth as an endpoint at all.

Is Chromium Picolinate Safe for the Kidneys, and Does It Damage DNA?

Two published case reports describe kidney injury following chromium picolinate use: one, a case of chronic renal failure after over-the-counter chromium picolinate; the other, a 24-year-old man who developed acute tubular necrosis requiring dialysis after two weeks on a multi-ingredient workout supplement containing chromium picolinate alongside three other stimulant ingredients — an “objective causality assessment” called the chromium link “probable,” not certain, given the other ingredients present. Neither case proves picolinate caused the injury on its own, and both are rare enough that no one has established an incidence rate. The U.S. Food and Nutrition Board reviewed this evidence and found it too limited to set a numeric upper intake for chromium — but it specifically flagged people with kidney or liver disease as more susceptible to harm from high chromium intakes, which is a caution, not a clean bill of safety.

A separate and unresolved question is genetic: a 1995 laboratory study found chromium picolinate caused chromosome damage in Chinese hamster ovary cells at 3 to 18 times the control rate, and traced the effect to the picolinate portion of the molecule rather than the chromium itself — chromium chloride and chromium nicotinate produced no damage at equivalent doses in the same experiment. A 2005 study using a similar cell-line method found no chromosome damage from chromium picolinate at all. The two findings directly contradict each other, and a decade of further lab work has not settled which one generalises. No study has shown this bench finding translates into cancer or genetic harm in people taking normal supplement doses, but the absence of human data means the question is open, not answered.

Can Chromium Picolinate Cause Low Blood Sugar With Metformin or Insulin?

Yes — chromium may itself increase insulin sensitivity, and taking it alongside insulin can raise the risk of hypoglycaemia, according to the NIH Office of Dietary Supplements chromium fact sheet; the same source notes an additive glucose-lowering effect with metformin and other antidiabetes medications carries the same risk. Hypoglycaemia feels like shakiness, sweating, a racing heartbeat, sudden intense hunger, and difficulty concentrating, developing over minutes; left untreated it can progress to confusion, slurred speech, or loss of consciousness. If you take insulin or metformin and want to add chromium picolinate, tell your prescriber first so your glucose can be monitored while you start — this is exactly the kind of addition worth raising at a metformin follow-up rather than trying alongside it unsupervised. Separately, one small study found taking chromium picolinate at the same time as levothyroxine reduced levothyroxine absorption over six hours — reason enough to space the two doses apart if you take both.

Who Won’t Chromium Picolinate Help?

If insulin resistance isn’t part of your picture, the mechanism chromium is proposed to work through has less to act on — the same logic that makes metformin’s effect size modest in lean phenotypes applies here, though no trial has tested chromium picolinate by PCOS phenotype directly. The 2023 international PCOS guideline does not name chromium among its recommended treatments at all; its evidence-based recommendations center on lifestyle change, letrozole, and metformin, and chromium picolinate sits outside that reviewed evidence base. Nobody has tested it in pregnancy or breastfeeding, so there is no dosing information for those readers. And if the outcome you actually care about is a live birth or a positive pregnancy test, no trial in this review measured that endpoint — the closest data point, Amooee’s head-to-head trial, found no ovulation or pregnancy advantage over metformin, which itself is not the guideline’s first-line fertility drug.

Your Next Step

If insulin resistance is the reason you’re considering this, insulin resistance and PCOS covers what the marker actually measures and why the mechanism matters more than the supplement aisle suggests. For a prescription option with a larger and more consistent trial base on the same mechanism, metformin for PCOS covers the trade-offs; for another supplement proposed through the insulin pathway, berberine for PCOS has its own dose and safety data. And if you’re comparing chromium against another narrow-margin mineral sometimes stacked alongside it, selenium for PCOS covers a supplement where the safety margin, not the dose, is the whole story. For a direct side-by-side against berberine on evidence, dose, cost and interaction risk, see chromium picolinate compared against berberine. The rest of the supplements and medications section covers what else has trial evidence in PCOS.